1.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: ECP RIT, NCT00179790
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: BMT 0499 Solid, NCT00179816
|
|
3.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 months to 35 years
Sponsor: NCI
Protocol IDs: 070206, 07-C-0206, NCT00923351
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 to 35
Sponsor: NCI
Protocol IDs: NCI-02-C-0259, NCT00047372
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: PSCI-2003-232, NCT00084695
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992
|
|
8.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 11 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04720, NCT00617890
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP13-0707, EudraCT Number: 2007-006719-21, NCT00668148
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UMCC 2008.049, NCT00743509
|
|
14.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 30 years
Sponsor: NCI
Protocol IDs: COG-ADVL0821, ADVL0821, NCT00831844
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0121, NCI-41, 41, NCT00020163
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-02-C-0031, 02-C-0031, 5425, NCI-5425, NCT00030108
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI
Protocol IDs: UIHC-200008086, NCI-V02-1710, NCT00049023, 200008086
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03133, NCT00089245
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: PSCI-20615, NCT00112645
|
|
20.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-06-C-0152, NCI-P6571, NCT00354848, ZENECA-D8480C00016
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IMMUNO-C10/IVB/002, IMMUNO-002, MDA-2004-0557, NCT00346385
|
|
22.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI
Protocol IDs: NCI-07-C-0040, NCI-P6981, NCT00428272
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: NCI
Protocol IDs: NCI-08-C-0007, 08-C-0007, NCI-P6068, 7458, NCT00556881
|
|
24.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 70 and under
Sponsor: NCI
Protocol IDs: UMN-2005LS023, UMN-2005LS023, UMN-MT2004-30, NCT00623077
|
|
25.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: MDA-2007-0595, 2007-0595, 8109, NCT00678223
|
